background nuclear magnetic resonance nmr spectroscopy measures the number and size of lipoprotein particles instead of their cholesterol or triglyceride content but its clinical utility is uncertainmethods and results baseline lipoproteins were measured by nmr in 27673 initially healthy women followed for incident cardiovascular disease cvd n1015 over 11 yearsadjusting for nonlipid risk factors hazard ratios hrs and 95 confidence intervals cis for top vs bottom quintile of nmrmeasured lipoprotein particle concentration particlesl were for lowdensity lipoprotein ldlnmr 251 191330 highdensity lipoprotein hdlnmr 091 075112 verylowdensity lipoprotein vldlnmr 171 138212 and ldlnmrhdlnmr ratio 225 180281similarlyadjusted results for nmrmeasured lipoprotein particle size nanometers were for ldlnmr size 064 052079 hdlnmr size 065 051081 and vldlnmr size 137 110170hazard ratios for nmr measures were comparable but not superior to standard lipids total cholesterol 208 163267 ldl cholesterol 174 140216 hdl cholesterol 052 042064 triglycerides 258 195341 nonhdl cholesterol 252 195325 totalhdl cholesterol ratio 282 223358 and apolipoproteins b100 257 198333 a1 063 052077 b100a1 ratio 279 221354there was essentially no reclassification improvement with adding ldlnmr particle concentration or apolipoprotein b100 to a model that already included the totalhdl cholesterol ratio and nonlipid risk factors net reclassification index nri 0 and 19 respectively nor did the addition of either variable result in a statistically significant improvement in the cindexconclusions in this prospective study of healthy women cvd risk prediction associated with lipoprotein profiles evaluated by nmr was comparable but not superior to standard lipids or apolipoproteins